CTN 331: DDI Study: Drug-drug interactions between ART and feminizing hormones in trans women living with HIV
Drug-drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIVLearn More
Development and validation of an anal cancer screening algorithm in HIV-positive men who have sex with menLearn More
Optimising Outcomes at Critical Points in the Cascade of HIV Care in OntarioLearn More
The impact of COVID-19 on persons with HIV in Canada: Data from the HIV/HCV co-infection/CCC (CTN 222) and HIV aging cohorts (CTN 314)Learn More
Electronic capture through the Opal patient portal of a patient-reported measure of barriers to antiretroviral therapy adherence: a mixed method type 3 hybrid pilot study at a large Montreal HIV clinicLearn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.